NCT06484127Completed
Heterogeneity of Tertiary Lymphoid Structures Predicts Distinct Malignancy and Immune Microenvironment in Prostate Cancer: a Retrospective Cohort Study
Source: ClinicalTrials.gov · Last updated 3 Jul 2024
Brief summary (registry, in English)
The aim of this study was to reveal the predictive value of spatial heterogeneity and maturity difference of tertiary lymphoid structure in pathological sections of prostate cancer patients for clinical features and prognosis. It provides a new idea for the selection of prostate cancer immunotherapy population in the future.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 200 (actual)
- First submitted
- 26 Jun 2024
- Start date
- 1 Dec 2023
- Primary completion date
- 30 May 2024
- Lead sponsor
- Fudan University
- Diseases
- Prostate cancer, Childhood cancers
- NCT number
- NCT06484127
What you commit to
- Study type: Observational
- Participants enrolled: 200
- From 1 Dec 2023 to the primary completion date, 30 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\. incomplete medical records, inadequate follow-up information, and confirmed non-prostatic acinar adenocarcinoma.
Who the study is looking for
- 1.patients diagnosed with prostate cancer who underwent radical prostatectomy or prostate puncture
Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.